Seaport Therapeutics (SPTX) reported third-quarter 2026 financial results and clinical progress, including a Phase 1 driving trial that met its primary endpoint. GlyphAllo 375 mg did not impair next-morning simulated driving versus placebo on Day 5 after multiple-day dosing; the secondary endpoint was also met, with no serious adverse events reported.
Quarterly net loss widened to $26.394 million from $22.544 million a year earlier. Cash, cash equivalents and investments totaled $403.799 million at September 30, 2026. Seaport expects funding into 2029 through three clinical readouts: GlyphAllo Phase 2b depression data in the first half of 2027, GlyphAgo Phase 2a anxiety and sleep-disturbance data in early 2028, and GlyphAgo Phase 2/3 anxiety data by year-end 2028. The first Phase 2a patient was dosed in October; Seaport plans to start the Phase 2/3 trial in the first half of 2027.
Seaport Therapeutics (SPTX) will present at the Stifel 2026 Healthcare Conference on November 10, 2026, at 4:00 p.m. EST. The conference runs November 10–12 at the Lotte New York Palace Hotel in New York City. Management will also participate in one-on-one investor meetings. A live webcast will be available through the company’s investor website, with an archived replay available after the presentation.
PureTech Health (PRTC) announced that founded entity Seaport Therapeutics (SPTX) is presenting additional Phase 1 data for GlyphAgo at ECNP.
The completed trial enrolled 174 healthy volunteers. GlyphAgo achieved a statistically significant 6.8-fold increase in agomelatine bioavailability and 10-fold lower pharmacokinetic variability versus unmodified agomelatine. Pharmacokinetics describes drug exposure in the body. Additional analyses showed dose-dependent exposure, no food effect and no exposure accumulation over seven days of dosing. Estrogen-containing oral contraceptives did not affect agomelatine exposure following GlyphAgo dosing.
Seaport has initiated a Phase 2a trial in adults with generalized anxiety disorder and sleep disturbance, with results expected in early 2028. It plans a Phase 2/3 trial in generalized anxiety disorder in the first half of 2027.
Seaport Therapeutics (Nasdaq: SPTX) announced additional Phase 1 GlyphAgo data for presentation at the ECNP Congress on October 11, 2026. The completed trial enrolled 174 healthy volunteers. GlyphAgo achieved a statistically significant 6.8-fold increase in agomelatine bioavailability, the amount reaching circulation, and 10-fold lower variability in drug exposure versus unmodified agomelatine.
Additional analyses showed dose-dependent exposure increases, no food effect and no accumulation over seven days of dosing. Estrogen-containing oral contraceptives did not affect exposure. Comparable exposure was achieved at lower doses; Seaport believes its approach could reduce liver enzyme elevations. A Phase 2a trial in adults with generalized anxiety disorder and sleep disturbance has begun, with results expected in early 2028. Seaport plans a Phase 2/3 trial in generalized anxiety disorder in the first half of 2027.
PureTech Health (PRTC) announced its founded entity Seaport Therapeutics (SPTX) dosed the first patient in a Phase 2a GlyphAgo trial. The six-week Australian study enrolls adults with generalized anxiety disorder and sleep disturbance. It evaluates sleep outcomes to establish evidence of the drug's biological activity, alongside anxiety severity, safety and drug exposure. Seaport expects topline results in early 2028.
In Phase 1 healthy volunteers, GlyphAgo demonstrated a statistically significant 6.8-fold increase in bioavailability, the amount of drug reaching circulation, versus unmodified agomelatine. After seven days of once-daily dosing, the tested doses were well tolerated, with no serious, severe or liver-related adverse events. Seaport plans to start a global, placebo-controlled Phase 2/3 trial in the first half of 2027, with topline results expected by the end of 2028.
Seaport Therapeutics (SPTX) has dosed the first patient in its Phase 2a GlyphAgo trial for generalized anxiety disorder and sleep disturbance. The six-week Australian trial randomly assigns adults to 16 mg/day or 32 mg/day in a double-blind design. It evaluates sleep outcomes, anxiety severity, safety and drug exposure. Seaport expects topline data in early 2028.
In healthy volunteers, Phase 1 showed a statistically significant 6.8-fold increase in bioavailability, the amount of drug reaching circulation, versus unmodified agomelatine. After seven days of once-daily dosing, both doses achieved therapeutically relevant exposure, with no serious or severe adverse events, liver-related adverse events or clinically significant liver laboratory changes. Seaport plans to start a global, placebo-controlled Phase 2/3 trial in the first half of 2027, with topline data expected by the end of 2028.
Seaport Therapeutics (SPTX)/b) will participate in several investor conferences in September 2026, featuring a company presentation and panel with Co-Founder and CEO Daphne Zohar at the Goldman Sachs Life Sciences Symposium on September 15, 2026.Seaport management plans one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference from September 14–16, the Goldman Sachs Life Sciences Symposium on September 15, and the Deutsche Bank 2026 Healthcare Summit from September 15–17. On September 23, 2026, management will join a fireside chat at 10:00 a.m. ET during the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit. Live webcasts and archived replays of Seaport’s presentations will be available via the Investors section of its website.
Seaport Therapeutics (SPTX) reported positive topline results from a Phase 1 driving simulation trial of GlyphAllo™ (SPT-300) in healthy volunteers.
The primary endpoint was met: evening dosing of 375 mg GlyphAllo did not impair next-morning driving performance versus placebo on Day 5 after multiple-day dosing. A key secondary endpoint was also met, as a single evening dose of 250 mg showed no next-morning driving impairment versus placebo on Day 2. A 7.5 mg dose of zopiclone, used as a positive control, produced statistically significant impairment versus both GlyphAllo and placebo, confirming assay sensitivity. GlyphAllo was well-tolerated at all doses with no serious adverse events reported. Seaport plans to submit the data to the FDA and is enrolling BUOY-1, a potentially registration-enabling Phase 2b MDD trial, with topline data expected in the first half of 2027.
Seaport Therapeutics (SPTX) reported positive topline results from a Phase 1 driving simulation trial of its oral neurosteroid prodrug GlyphAllo (SPT-300) in 33 healthy volunteers.
The primary endpoint was met: evening dosing of 375 mg GlyphAllo did not impair next-morning driving performance versus placebo on Day 5 after multiple-day dosing. A key secondary endpoint was also met, showing that a single evening dose of 250 mg did not impair next-morning driving on Day 2 versus placebo. Driving performance was measured by Standard Deviation of Lateral Position (SDLP) using a validated Cognitive Research Corporation Driving Simulator-MiniSim.
Zopiclone 7.5 mg, used as a positive control, produced statistically significant impairment versus both GlyphAllo and placebo on Days 2 and 5, confirming assay sensitivity. GlyphAllo was well-tolerated at all doses, with mostly mild, transient adverse events and no serious adverse events. Seaport plans to submit the results to the U.S. FDA and is enrolling the potentially registration-enabling Phase 2b BUOY-1 MDD trial, with topline data expected in the first half of 2027.
Seaport Therapeutics (Nasdaq: SPTX) announced that its management team will participate in two investor events in September 2026. The company will attend the 21st Annual Wells Fargo Healthcare Conference from September 8–10, 2026, where it plans to hold one-on-one investor meetings.
Seaport will also join Citi’s 2026 Biopharma Back to School Conference from September 9–10, 2026, including a fireside chat on September 9, 2026 at 1:00 p.m. ET and one-on-one investor meetings. A live webcast and archived replay of the Citi fireside chat will be available in the Investors section of Seaport’s website.